Table 2.
Total iPGVs and alterations in actionable genes detected in our cohort.
| Total iPGVs | n = 21 (%) |
|---|---|
| ATM | 10 (47.6%) |
| A1299fs | 1 (10%) |
| E1751fs | 1 (10%) |
| K468fs | 1 (10%) |
| R1882 | 1 (10%) |
| R2832C | 1 (10%) |
| R3008C | 1 (10%) |
| Q1970 | 1 (10%) |
| Splice Site SNV | 3 (30%) |
| BRCA2 | 8 (38.1%) |
| E1308 | 1 (12.5%) |
| K1530 | 1 (12.5%) |
| N257fs | 1 (12.5%) |
| Q2042 | 1 (12.5%) |
| Q2943fs | 1 (12.5%) |
| S142I | 1 (12.5%) |
| S1882 | 1 (12.5%) |
| T1707fs | 1 (12.5%) |
| BRCA1 | 3 (14.3%) |
| K894fs | 1 (33.3%) |
| L392fs | 1 (33.3%) |
| T276fs | 1 (33.3%) |
| Total Alterations in Targetable Genes | 9 (24.9% total) |
| EGFR | 6 (28.6% total) |
| EGFR L858 | 1 (16.7%) |
| EGFR exon 19 deletion | 1 (16.7%) |
| EGFR exon 20 insertion | 1 (16.7%) |
| EGFR other | 3 (50%) |
| BRAF V600E | 1 (4.8% total) |
| BRAF V600E | 1 (100%) |
| KRAS | 2 (9.5% total) |
| KRAS G12V | 1 (50%) |
| KRAS L19F | 1 (50%) |
This table lists by row the number of iPGVs or total alterations in targetable genes within our cohort in the first column. Totals and corresponding percentages are listed in the second column.